Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Joaquina Baranda"'
Autor:
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Abushukair, Kelly Mulvaney, Andrew K. Godwin, Azhar Saeed
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS t
Externí odkaz:
https://doaj.org/article/ef214cc1e88d4bb382653082f8b6a181
Autor:
Weijing Sun, Nirmal Veeramachaneni, Raed Al‐Rajabi, Rashna Madan, Anup Kasi, Mazin Al‐Kasspooles, Joaquina Baranda, Anwaar Saeed, Milind A. Phadnis, Andrew K. Godwin, Mojtaba Olyaee, Natalie Streeter, Alykhan Nagji, Junqiang Dai, Stephen Williamson
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16098-16107 (2023)
Abstract Background Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to a
Externí odkaz:
https://doaj.org/article/613b6c3bdc634b1eace9ff580f7c8506
Autor:
Neesha Dhani, Antonio Jimeno, Michael S Gordon, Matthew H Taylor, Howard Bernstein, Scott Loughhead, Joaquina Baranda, Udo Holtick, Jong Chul Park, Wade T Iams, Monica MitaSc, Kerry J Rodabaugh, E Amanda Duvall, Julia Jennings, Nathan Miselis, Marshelle S Warren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b406701e0de64534a5d175828eea4fcf
Autor:
Ian M. Freed, Anup Kasi, Oluwadamilola Fateru, Mengjia Hu, Phasin Gonzalez, Nyla Weatherington, Harsh Pathak, Stephen Hyter, Weijing Sun, Raed Al-Rajabi, Joaquina Baranda, Mateusz L. Hupert, Prabhakar Chalise, Andrew K. Godwin, Malgorzata A. Witek, Steven A. Soper
Publikováno v:
Cells, Vol 12, Iss 18, p 2266 (2023)
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an in
Externí odkaz:
https://doaj.org/article/9fecc40105aa4e958c30860a3c5755e3
Autor:
Ghulam Rehman Mohyuddin, Muhammad Aziz, Alec Britt, Lee Wade, Weijing Sun, Joaquina Baranda, Raed Al-Rajabi, Anwaar Saeed, Anup Kasi
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is unclear whe
Externí odkaz:
https://doaj.org/article/866273a944434fd5ad321569c2fb5010
Autor:
Adil Daud, Ezra Cohen, Matthew Reilley, Siwen Hu-Lieskovan, Shubham Pant, Raphael Clynes, Roger Cohen, Anthony Shields, Mark Stein, Alain Mita, Bartosz Chmielowski, Yana Najjar, Elaine Shum, Joaquina Baranda, R Donald Harvey, Catherine Fleener, Ying Ding, Sowmya Chollate, Jolene Shorr, Barbara Hickingbottom, Lei Bao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6a7db806111f4ca8b46be50a0a23239a
Autor:
Vivek Subbiah, Capucine Baldini, Kristen Spencer, Luis Manso, Armando Santoro, Sandip Patel, Joaquina Baranda, Ira Winer, Akhila Wimalasingham, Linda Duska, Polina Khrizman, Griet Van Lancker, Lana Andrianova, Sumandeep Atwal, Keerti Sharma
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac09e478413646eb8f4ebcda129483b0
Autor:
Filip Janku, Matthew Taylor, Michael Gordon, Cathy Eng, Antonio Jimeno, Joaquina Baranda, Ursula Matulonis, Martin Kornacker, Asha Kamat, Oliver Rosen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/3cc2904d3a334486ad427a8087759afe
Publikováno v:
Oncology Reviews, Vol 5, Iss 2 (2011)
Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer. Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous infusion of 5-FU while avoiding complications and inconvenience of intravenous adminis
Externí odkaz:
https://doaj.org/article/42318c25350f4a4582168a721602820d
Autor:
MOHAMMED AL-JUMAYLI, KHALIL CHOUCAIR, AMMAR AL-OBAIDI, ROBIN PARK, AJAY BANSAL, JOAQUINA BARANDA, WEIJING SUN, ANWAAR SAEED
Publikováno v:
Anticancer Research. 42:59-66